A recent Morbidity and Mortality Weekly Report highlights the risks associated with use of over-the-counter products containing undeclared prescription ingredients as well as the importance of collaboration between various health departments and systems to ensure a prompt response to an outbreak.
The CDC has reported observing a significant increase in the number of meningococcal disease cases with isolates containing a blaROB-1 β-lactamase enzyme gene, conferring resistance to penicillin antibiotics and, in some cases, ciprofloxacin as well.
Due to a lack of evidence on the safety of the ingredients used in topical pain cream, caution should be exercised when prescribing these preparations.
Previous research has suggested that treatment with metformin may potentially lower the risk of dementia, however whether the timing of treatment impacts this result remains unclear.
Due to her neurologic presentation, age, and past medical history, stroke was initially considered.
In order to provide national guidance addressing issues surrounding pain management practices, an expert panel was convened to provide a framework for pain practitioners and institutions.
Treatment with AXS-07, an investigational therapy being developed by Axsome Therapeutics, substantially reduced migraine pain and significantly prevented the progression of migraine pain intensity, according to results of the phase 3 INTERCEPT trial.
Among patients with OAB, anticholinergic medication use appears to be associated with an increased risk of new onset dementia when compared with beta-3 agonist use, according to the findings of a retrospective population-based cohort study.
Analysis of the data revealed that 54 RCTs and 17 NRSs included in the qualitative synthesis “reported at least a significant result” favoring the use of lavender for anxiety.
